YORK, May 13, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Homology Medicines, Inc.
To receive updates on the lawsuit, fill out the
The lawsuit seeks to recover losses for shareholders who
purchased Homology between June 10,
2019 and February 18, 2022.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
May 24, 2022 to petition the
court. Your ability to share in any recovery doesn't require that
you serve as a lead plaintiff.
According to a filed complaint, Homology Medicines, Inc. issued
materially false and/or misleading statements and/or failed to
disclose that: (i) the Company had overstated the efficacy and risk
mitigation of its lead product candidate, HMI-102; (ii)
accordingly, it was unlikely that the Company would be able to
commercialize HMI102 in its present form; and (iii) as a result,
the Company's public statements were materially false and
misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE Jakubowitz Law